Literature DB >> 2114998

Partial tolerance in beta-galactosidase-transgenic mice.

U Theopold1, G Köhler.   

Abstract

A transgenic mouse line was produced which allowed the expression of E. coli beta-galactosidase (beta-Gal) under the regulatory elements of the immunoglobulin heavy chain locus. Expression of the transgene is found in spleen and bone marrow. Upon immunization of the transgenic mice with beta-Gal, a reduced but clearly detectable antibody response was obtained. Affinity purification with sera from immunized transgenic mice suggests that they contain lower affinity antibodies as compared to normal littermates. Transgenic and nontransgenic mice immunized with bovine serum albumin (BSA) alone or as a mixture with beta-Gal gave comparable anti-BSA responses. Immunization with a chemically cross-linked (Gal-BSA)-protein, however, showed a 10- to 30-fold difference in the anti-BSA response. Partial unresponsiveness to beta-Gal in the transgenic mice is best explained by a dominant, peripheral suppression mechanism linked to the antigen-presenting potential of B cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114998     DOI: 10.1002/eji.1830200617

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  3 in total

1.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

Authors:  M Wang; V Bronte; P W Chen; L Gritz; D Panicali; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

Review 2.  Analysis of enamel development using murine model systems: approaches and limitations.

Authors:  Megan K Pugach; Carolyn W Gibson
Journal:  Front Physiol       Date:  2014-09-17       Impact factor: 4.566

3.  Endothelial cells present antigens in vivo.

Authors:  Annette L Rothermel; Yinong Wang; Jeffrey Schechner; Barry Mook-Kanamori; William C Aird; Jordan S Pober; George Tellides; David R Johnson
Journal:  BMC Immunol       Date:  2004-03-16       Impact factor: 3.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.